Your browser doesn't support javascript.
loading
Detection of metastases using circulating tumour DNA in uveal melanoma.
Beasley, Aaron B; de Bruyn, Daniël P; Calapre, Leslie; Al-Ogaili, Zeyad; Isaacs, Timothy W; Bentel, Jacqueline; Reid, Anna L; Dwarkasing, Roy S; Pereira, Michelle R; Khattak, Muhammad A; Meniawy, Tarek M; Millward, Michael; Brosens, Erwin; de Klein, Annelies; Chen, Fred K; KiliÒ«, Emine; Gray, Elin S.
Afiliação
  • Beasley AB; School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia. a.beasley@ecu.edu.au.
  • de Bruyn DP; Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia. a.beasley@ecu.edu.au.
  • Calapre L; Department of Ophthalmology, Erasmus MC, 3000 CA, Rotterdam, The Netherlands.
  • Al-Ogaili Z; Department of Clinical Genetics, Erasmus MC, 3000 CA, Rotterdam, The Netherlands.
  • Isaacs TW; Erasmus MC Cancer Institute, 3000 CA, Rotterdam, The Netherlands.
  • Bentel J; School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
  • Reid AL; Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia.
  • Dwarkasing RS; Department of Molecular Imaging and Therapy Service, Fiona Stanley Hospital, Murdoch, WA, 6150, Australia.
  • Pereira MR; Perth Retina, Subiaco, WA, Australia.
  • Khattak MA; Centre for Ophthalmology and Visual Science (Incorporating Lions Eye Institute), The University of Western Australia, Crawley, WA, Australia.
  • Meniawy TM; Department of Ophthalmology, Royal Perth Hospital, Perth, WA, Australia.
  • Millward M; Anatomical Pathology, PathWest Laboratory Medicine, Fiona Stanley Hospital, Murdoch, WA, Australia.
  • Brosens E; School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
  • de Klein A; Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia.
  • Chen FK; Department of Radiology, Erasmus MC, 3000 CA, Rotterdam, The Netherlands.
  • KiliÒ« E; School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
  • Gray ES; School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
J Cancer Res Clin Oncol ; 149(16): 14953-14963, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37608028
BACKGROUND: Approximately 50% of uveal melanoma (UM) patients will develop metastatic disease depending on the genetic features of the primary tumour. Patients need 3-12 monthly scans, depending on their prognosis, which is costly and often non-specific. Circulating tumour DNA (ctDNA) quantification could serve as a test to detect and monitor patients for early signs of metastasis and therapeutic response. METHODS: We assessed ctDNA as a biomarker in three distinct UM cohorts using droplet-digital PCR: (A) a retrospective analysis of primary UM patients to predict metastases; (B) a prospective analysis of UM patients after resolution of their primary tumour for early detection of metastases; and (C) monitoring treatment response in metastatic UM patients. RESULTS: Cohort A: ctDNA levels were not associated with the development of metastases. Cohort B: ctDNA was detected in 17/25 (68%) with radiological diagnosis of metastases. ctDNA was the strongest predictor of overall survival in a multivariate analysis (HR = 15.8, 95% CI 1.7-151.2, p = 0.017). Cohort C: ctDNA monitoring of patients undergoing immunotherapy revealed a reduction in the levels of ctDNA in patients with combination immunotherapy. CONCLUSIONS: Our proof-of-concept study shows the biomarker feasibility potential of ctDNA monitoring in for the clinical management of uveal melanoma patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: DNA Tumoral Circulante / Melanoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: DNA Tumoral Circulante / Melanoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article